Cancer Cell

Article	Citations
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer	2722
Long-range cholinergic input promotes glioblastoma progression	673
Lymphoma accelerates T cell and tissue aging	656
KIT as a therapeutic target in neuroendocrine prostate cancer	496
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression	474
Characterization of the generic mutant p53-rescue compounds in a broad range of assays	433
TAMing immunity through an unexpected source	423
A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture	417
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer	408
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas	385
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer	345
Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions	340
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition	338
IL-36γ armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity	337
Accelerated approvals: Early-phase success or premature authorization?	320
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients	309
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling	294
Diet-microbiome interactions in cancer	290
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton	288
Spatial profiling technologies illuminate the tumor microenvironment	284
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer	281
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations	276
Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target	274
T cell dynamism and immune-related adverse events	273
T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation	272

A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma	269
B cell heterogeneity in cancer comes of age	264
Cancer vaccines	256
The aging lung microenvironment awakens melanoma metastases	255
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron	254
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer	249
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity	232
Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses	228
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses	225
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	223
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer	214
Bacteria in metastatic sites: Unveiling hidden players in cancer progression	208
Challenges in neoantigen-directed therapeutics	206
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer	203
A holistic view of cancer	202
When the methylome becomes the microscope	201
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments	195
High endothelial venules in cancer: Regulation, function, and therapeutic implication	194
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma	193
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors	191
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer	186
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer	180
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin	176
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts	175
A genetic portrait of metastatic seeds in lung adenocarcinoma	174
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?	172
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer	172
Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding	172
Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells	172
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population	169
Challenges and opportunities for modeling aging and cancer	169
Targeting STING to generate therapeutic anti-tumor immunity	168
The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors	167
Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas	166
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation	166
Immunosensitivity cuts across mismatch repair status in colorectal cancer	164
Revisiting TNM staging for EBV-related nasopharyngeal carcinoma	163
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression	161
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma	161
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation	159
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy	159
Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma	155
Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma	152
Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer	147
Hypoxia inducible factor-1α drives cancer resistance to cuproptosis	145
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer	143
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients	140
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy	140
Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics	138
Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies	137

Response-based molecular subtyping—emergence of the third generation of breast cancer subtypes	136
Circulating tumor DNA as a biomarker in early phase clinical trials	136
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers	136
Midkine as a driver of age-related changes and increase in mammary tumorigenesis	135
Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions	134
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma	134
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD	132
A path to translation: How 3D patient tumor avatars enable next generation precision oncology	131
Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring	131
Immune determinants of the pre-metastatic niche	130
Tumor-infiltrating lymphocytes: A new hope	130
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness	128
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis	128
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment	127
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells	127
Integrated proteogenomic characterization of glioblastoma evolution	125
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1	124
Taxanes directly induce T cell cytotoxic extracellular vesicles to eradicate tumor cells	123
GDF15 research from bench to bedside	123
Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy	123
The winner takes it all: Competition drives clonal selection in gliomagenesis	120
Firing up neutrophil anti-tumor immunity with cocktails	119
A circular RNA in neuroendocrine carcinomas	119
Tumors on different wavelengths	118
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma	118
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study	117
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma	116
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial	114
T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers	113
New horizons at the interface of artificial intelligence and translational cancer research	111
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma	109
Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest	108
Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance	107
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer	107
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma	107
Proteogenomic data and resources for pan-cancer analysis	107
Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma	107
Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment	105
Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma	104
GD2-CAR T cells in patients with osteosarcoma and neuroblastoma—it’s not only the T cells that matter	104
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma	104
Cellular senescence in precancer lesions and early-stage cancers	102
Lactobacillus reuteri—an old acquaintance takes on a new task in colorectal tumor surveillance	102
Hidden spark: From cold to hot in BRAF colorectal cancer	100
When blood mutations turn beneficial	100
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer	98
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma	98
Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers	97
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models	95
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer	95
CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4	94
Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer	93
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia	92
Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer	92
Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures	91
Plasma cell and cancer stem cell crosstalk in glioblastoma	91
Stromal barriers to the abscopal effect	90
PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer	89
From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space	87
Stromal lipid species dictate melanoma metastasis and tropism	87
Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity	86
Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy	84
Engineering myeloid cells for cancer immunotherapy	84
Seed or soil: Tracing the immune subsets in metastatic tumors	84
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity	83
Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis	83
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers	83
Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study	82
Tumor microbiome links cellular programs and immunity in pancreatic cancer	82
High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer	81
Horizontal mitochondrial transfer in cancer biology: Potential clinical relevance	81
Glioblastoma induces the recruitment and differentiation of dendritic-like “hybrid” neutrophils from skull bone marrow	81
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers	80
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	80
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy	79
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice	79
Identification of specific PP2A complexes involved in human cell transformation	77
Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial	77
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative	76
Architecture sets the path: Breast cancer subtypes differently shape the early brain metastatic niche	76

Spatial patterns of glioblastoma	76
Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma	75
Vascular characterization reveals immunomodulatory targets for brain metastases	75
When immunotherapy meets surgery in non-small cell lung cancer	75
Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding	73
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	73
Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer	73
Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC	73
Subclonal immune evasion in non-small cell lung cancer	73
Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition	73
When essential metal elements become culprits—Cuproptosis in focus	72
Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence	72
Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer	72
A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma	71
Revealing de novo pyrimidine synthesis as a key vulnerability in brain tumors	71
A first-in-class EGFR-directed KRAS G12V selective inhibitor	71
Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression	70
Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity	70
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site	70
Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications	69
TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak	69
A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression	68
Genomic mapping of metastatic organotropism in lung adenocarcinoma	68
Neutrophil-activating therapy for the treatment of cancer	67
Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance	67
Sex and cancer immunotherapy: Current understanding and challenges	66
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma	64
Overcoming melanoma therapy resistance with RAF-MEK and FAK inhibition	63
The coming era of nudge drugs for cancer	63
The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy	63
Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma	63
Bridging the gap: The future of cancer research and clinical oncology in Cancer Cell	63
Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade	63
Engineered natural killer cells for cancer therapy	62
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma	62
IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy	62
Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer	61
Carnobacterium maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice	61
Immune phenotypic linkage between colorectal cancer and liver metastasis	61
Insights into the co-evolution of epithelial cells and fibroblasts in the esophageal tumor microenvironment	60
Immune memory shapes ovarian cancer recurrence	60
Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread	60
Rethinking relief: Targeting sensory neurons to combat cancer and pain	59
Metabolic regulation of Cathepsin B in tumor macrophages drives their pro-metastatic function	59
Remodeling of T and endothelial cells during total neoadjuvant therapy in rectal cancer	58
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts	57
TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors	57
Alistipes finegoldii augments the efficacy of immunotherapy against solid tumors	57
Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis	57
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity	57
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment	56
Senescent alveolar macrophages promote early-stage lung tumorigenesis	56
A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis	55
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory	55
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers	54
Cooperative CAR targeting to selectively eliminate AML and minimize escape	54
Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer	54
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	54
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)	53
Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer	53
Probing cancer with small-molecule tools—Progress and challenges	52
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy	52
Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma	52
Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer	52
Tumor-reactive T helper cells in the context of vaccination against glioma	51
Engineering cancer’s end: An interdisciplinary approach to confront the complexities of cancer	51
Precision medicine in AML: Function plus -omics is better than either alone	51
Innate lymphoid cells recruit T cells to turn up the heat on tumors	51
Of HIFs and hERVs: Neoantigen generation in kidney cancer	51
The importance of ancestry to understanding tumor mutation burden in cancer	50
Leading medulloblastoma to a differentiation end	50
Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes	50
Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy	49
The temporal progression of lung immune remodeling during breast cancer metastasis	49
Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells	48
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors	48
Disarming myeloid resistance in CAR T therapy	48
Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy	48
Integrated electrophysiological and genomic profiles of single cells reveal spiking tumor cells in human glioma	48
Methionine restriction promotes cGAS activation and chromatin untethering through demethylation to enhance antitumor immunity	48
Integrating priorities at the intersection of cancer and neuroscience	48
Single-cell resolution spatial analysis of antigen-presenting cancer-associated fibroblast niches	47
Spatial transcriptomics	46
Cancer cell death: Cell-autonomous and immunogenic dimensions	46
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer	46
Envision the future of precision medicine in pediatric cancer	45
Biomimetic models in radiotherapy research: An essential bridge between bench and beam	45
Machine learning identifies experimental brain metastasis subtypes based on their influence on neural circuits	44
Inosine induces stemness features in CAR-T cells and enhances potency	44
What’s in a name? An emerging framework for cancer-associated fibroblasts, myofibroblasts, and fibroblasts	44
Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer	44
Protein-based classification reveals an immune-hot subtype in IDH mutant astrocytoma with worse prognosis	43
Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma	43
Engineered T cell therapy for viral and non-viral epithelial cancers	43
Fragmentomics profiling and quantification of plasma Epstein-Barr virus DNA enhance prediction of future nasopharyngeal carcinoma	43